What is Fusion Pharmaceuticals Inc. (FUSN)?

Fusion Pharmaceuticals Inc. (FUSN) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of FUSN?

The current price of FUSN is $21.55. Prices are updated in real time on Stocks360.

What is FUSN's price-to-earnings (PE) ratio?

FUSN's trailing twelve-month PE ratio is -14.86, based on current price and earnings per share data available on Stocks360.

What is FUSN's market capitalization?

FUSN's market capitalization is $1,833,043,000.00, placing it in the small-cap tier.

Fusion Pharmaceuticals Inc. (FUSN)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$21.55

Market Cap

$1.83B

PE (TTM)

-14.86

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

-0.69

Day Range

$21.48 – $21.58

52-wk Range

$2.31 – $21.60

Avg Volume

N/A

Volume

6.08M

Fusion Pharmaceuticals Inc. (FUSN) is a publicly traded company in the Healthcare sector. Latest price: $21.55. Market cap $1.83B. Trailing PE -14.86. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

May 7, 2024

EPS $-0.40 vs est. $-0.38

Missed by $0.02

Proprietary Signals

Signal snapshot temporarily unavailable.

About Fusion Pharmaceuticals Inc.

Fusion Pharmaceuticals Inc. is a clinical-stage oncology enterprise focused on creating precise radiopharmaceutical therapies. The company utilizes its groundbreaking Targeted Alpha Therapies platform, which incorporates its exclusive Fast-Clear linker technology. This innovative system enables the attachment of alpha particle-emitting isotopes to diverse targeting molecules, facilitating the targeted delivery of these potent payloads directly to cancerous growths. Its leading investigational compound, FPI-1434, is currently progressing through Phase 1 clinical trials as a singular treatment for individuals suffering from solid tumors that express the insulin-like growth factor 1 receptor. Beyond this, Fusion is conducting preclinical research into FPI-1434's effectiveness in conjunction with existing checkpoint inhibitors and DNA damage response inhibitors. These studies aim to thoroughly evaluate its anti-tumor effects, ideal dosage regimens, and pharmacological interactions within combination therapies. Furthermore, the firm is moving its earlier-stage candidate, FPI-1966, into clinical evaluation for the management of head and neck, and bladder cancers exhibiting fibroblast gr…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-14.86×
P/S (TTM)	886.38×
P/B	6.36×
P/FCF (TTM)	-21.39×
EV / EBITDA	-20.79×
EV / Sales	880.78×
Earnings Yield	-6.71%
Free Cash Flow Yield	-4.67%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$1.82B
Revenue (TTM)	$2.07M
Net Income (TTM)	-$123.03M
Free Cash Flow (TTM)	-$80.48M
Net Debt	-$11.59M
Working Capital	$227.18M
Gross Margin	34.96%
Operating Margin	-4798.45%
Net Margin	-4588.83%
Return on Equity	-49.34%
Return on Invested Capital	-36.25%